Latest News-Ascletis Pharma Inc. Mediaroom_Page

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and m...

2022-11-23 19:43 4659

Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

--While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval...

2022-11-17 08:10 4665

Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA

--Based on available data, ASC10 at the dosage of 800 mg twice daily was approved by the U.S. Food ...

2022-11-16 08:10 3644

Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

HANGZHOU and SHAOXING, China, Nov. 7, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Asclet...

2022-11-07 08:10 3474

Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin lik...

2022-11-02 08:10 3364

Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

--ASC10 has two indications: monkeypox and SARS-CoV-2 virus infections. The Investigational New Dru...

2022-10-26 20:10 3463

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

--The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60...

2022-10-10 08:10 2925

Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH

-- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroi...

2022-10-05 08:10 3544

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

-- After the pre-Phase III clinical trial meeting with Center for Drug Evaluation (CDE) of China Na...

2022-09-28 08:10 3214

Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection

HANGZHOU and SHAOXING, China, Sept. 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Asc...

2022-09-15 18:10 3380

Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA

-- Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhib...

2022-08-22 08:10 3584

Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study...

2022-08-16 08:10 3478

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors

--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significan...

2022-08-08 08:10 3435

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Aug. 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,...

2022-08-04 08:10 3971

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active...

2022-08-03 16:50 3382

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and ...

2022-07-06 08:10 4722

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascle...

2022-07-04 08:10 3517

Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection

-- The Phase II clinical study in China is currently expected to be completed in early 2023 with an...

2022-06-28 18:11 3268

Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg≤100 IU/mL Obtained Sustained HBsAg Loss

--Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for func...

2022-06-27 08:11 3710

Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022

- The updates of ASC22 Phase IIb study will be presented at the oral session during the Internation...

2022-06-16 08:10 3612